CJC-1295 with DAC vs TB-500 (Ac-LKKTETQ)
Well Studied vs Moderate Research
synergistic Mechanism-based · 47% CJC-1295 with DAC and TB-500 (Ac-LKKTETQ) work through complementary pathways. Growth hormone signaling supports tissue repair processes. A well-established combination in recovery protocols.
Molecular Data
CJC-1295 with DAC TB-500 (Ac-LKKTETQ)
Weight 3,647.28 Da 844 Da
Half-life 6-8 days Not precisely established; effects persist longer than 24 hours
Chain 30 amino acids 7 amino acids
Type GHRH analog with DAC Acetylated heptapeptide
Key Benefits
CJC-1295 with DAC
01 Convenient weekly dosing
02 Sustained GH/IGF-1 elevation
03 6-8 day half-life
04 Significant body composition changes
TB-500 (Ac-LKKTETQ)
01 Promotes wound healing
02 Enhances cell migration
03 Supports angiogenesis (new blood vessel formation)
04 Reduces inflammation
05 Promotes keratinocyte migration
06 Supports collagen deposition
07 Enhances tissue repair
08 Active region of thymosin beta-4
Dosing Protocols
CJC-1295 with DAC
1-2mg weekly / Once or twice weekly (e.g., Monday/Thursday for split dosing)
Conservative Anti-Aging 1mg Once weekly
Standard Protocol 2mg Once weekly
Split Dosing 1mg Twice weekly (Mon/Thu)
Loading Protocol 2mg first week, then 1mg Weekly
TB-500 (Ac-LKKTETQ)
2-2.5mg per injection / 2x weekly (e.g., Monday and Thursday)
Loading phase 2-2.5 mg 2x weekly for 4-6 weeks
Maintenance 2 mg Weekly or bi-weekly
Side Effects
CJC-1295 with DAC
Water retention
Joint pain
Carpal tunnel symptoms
TB-500 (Ac-LKKTETQ)
Injection site reactions
Mild fatigue
Head rush (reported)
Contraindications
Diabetes history
Cancer history
Predisposed sleep apnea
Not authorized for medicinal use
Active cancer (theoretical concern)
Pregnancy or breastfeeding
Prohibited by WADA in sports
Research Evidence
CJC-1295 with DAC TB-500 (Ac-LKKTETQ)
Status Well Studied Moderate Research
References 4 studies 4 studies
Latest 2025 —
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.